Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas (Q25257601)

6 July 2017

Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas (English)

1 reference

6 July 2017

8

Klaus Friese

1 reference

6 July 2017

7

0 references

author name string

Christian Schindlbeck

1

1 reference

6 July 2017

Theresa Kampik

2

1 reference

6 July 2017

Wolfgang Janni

3

1 reference

6 July 2017

Brigitte Rack

4

1 reference

6 July 2017

Udo Jeschke

5

1 reference

6 July 2017

Stan Krajewski

6

1 reference

6 July 2017

language of work or name

English

0 references

publication date

24 November 2005

1 reference

6 July 2017

Breast Cancer Research

1 reference

6 July 2017

7

1 reference

6 July 2017

6

1 reference

6 July 2017

R1174-85

1 reference

HER-2 gene amplification can be acquired as breast cancer progresses

6 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Cellular roles of dna topoisomerases: a molecular perspective

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

The Ki-67 protein: from the known and the unknown

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

The best use of chemotherapy in the adjuvant setting

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

HER-2/neu and topoisomerase IIalpha in breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

The ErbB receptors and their role in cancer progression.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

28 September 2017

TP53 and breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Roles of DNA topoisomerases in chromosome segregation and mitosis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Biology of HER2 and its importance in breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Prognostic impact of tumor biological factors on survival in node-negative breast cancer

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis

31 May 2018

1 reference

A pooled analysis of bone marrow micrometastasis in breast cancer

21 January 2018

1 reference

Spectrum of p53 tumor suppressor gene mutations and breast cancer survival

21 January 2018

1 reference

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

21 January 2018

1 reference

A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients

21 January 2018

1 reference

Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients

21 January 2018

1 reference

Evaluating HER2 amplification and overexpression in breast cancer.

21 January 2018

1 reference

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

21 January 2018

1 reference

Prognostic value of c-erbB2 expression in breast cancer

21 January 2018

1 reference

Influence of tumor biological factors on tumor cell dissemination in primary breast cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410751

Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer

28 November 2018

1 reference

12 December 2020

Molecular signature associated with bone marrow micrometastasis in human breast cancer

1 reference

12 December 2020

The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer

1 reference

12 December 2020

Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors

1 reference

12 December 2020

Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up

1 reference

12 December 2020

Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow

1 reference

12 December 2020

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer

1 reference

12 December 2020

Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells

1 reference

12 December 2020

Prognostic significance of p53 gene alterations in node-negative breast cancer

1 reference

12 December 2020

Overexpression of p53 and prognosis in breast cancer

1 reference

12 December 2020

p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases

1 reference

12 December 2020

The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry

1 reference

12 December 2020

Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer

1 reference

12 December 2020

First international ISHAGE symposium on minimal residual cancer

1 reference

12 December 2020

p53 oncoprotein as a prognostic indicator in patients with breast cancer

1 reference

12 December 2020

Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: Results of a 20-year median follow-up

1 reference

12 December 2020

Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases

1 reference

12 December 2020

Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer

1 reference

12 December 2020

Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?

1 reference

12 December 2020

Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients

1 reference

12 December 2020

Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer

1 reference

12 December 2020

Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables

1 reference

12 December 2020

Optimising the Role of Herceptin in Breast Cancer. Symposium proceedings. Monte Carlo, June 19-21, 2000

1 reference

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1186/BCR1360

1 reference

Dimensions Publication ID

6 July 2017

0 references

1 reference

6 July 2017

1 reference